Artal Group S.A. Incyte Corp Transaction History

Artal Group S.A.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2018 Aug 10, 2018	SELL	$60.85 - $83.98 $18.3 Million - $25.2 Million	-300,000 Closed	0 $0
Q1 2018 May 10, 2018	SELL	$83.06 - $100.98 $16.6 Million - $20.2 Million	-200,000 Reduced 40.0%	300,000 $25 Million
Q4 2017 Feb 09, 2018	BUY	$93.56 - $116.6 $9.36 Million - $11.7 Million	100,000 Added 25.0%	500,000 $47.4 Million
Q3 2017 Nov 08, 2017	BUY	$109.15 - $138.27 $43.7 Million - $55.3 Million	400,000	400,000 $46.7 Million

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.